Reece DE - Search Results

1

Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation.

Trieu Y, Trudel S, Pond GR, Mikhael J, Jaksic W, Reece DE, Chen CI, Stewart AK. Trieu Y, et al. Among authors: reece de. Mayo Clin Proc. 2005 Dec;80(12):1578-82. doi: 10.4065/80.12.1578. Mayo Clin Proc. 2005. PMID: 16342650

2

Hematopoietic stem cell transplantation in Hodgkin disease.

Reece DE. Reece DE. Curr Opin Oncol. 2002 Mar;14(2):165-70. doi: 10.1097/00001622-200203000-00005. Curr Opin Oncol. 2002. PMID: 11880706 Review.

3

Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer.

Reece DE, Foon KA, Bhattarcharya-Chatterjee M, Adkins D, Broun ER, Connaghan DG, Dipersio JF, Holland HK, Howard DA, Hale GA, Klingemann HG, Munn RK, Raptis A, Phillips GL. Reece DE, et al. Clin Breast Cancer. 2003 Feb;3 Suppl 4:S152-7. doi: 10.3816/cbc.2003.s.005. Clin Breast Cancer. 2003. PMID: 12620153 Clinical Trial.

4

Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.

Wechalekar AD, Chen CI, Sutton D, Reece D, Voralia M, Stewart AK. Wechalekar AD, et al. Leuk Lymphoma. 2003 Jul;44(7):1147-9. doi: 10.1080/1042819031000067918. Leuk Lymphoma. 2003. PMID: 12916866 Review.

5

Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.

Mollee PN, Wechalekar AD, Pereira DL, Franke N, Reece D, Chen C, Stewart AK. Mollee PN, et al. Bone Marrow Transplant. 2004 Feb;33(3):271-7. doi: 10.1038/sj.bmt.1704344. Bone Marrow Transplant. 2004. PMID: 14647248

6

Autologous stem cell transplantation in multiple myeloma patients <60 vs >/=60 years of age.

Reece DE, Bredeson C, Pérez WS, Jagannath S, Zhang MJ, Ballen KK, Elfenbein GJ, Freytes CO, Gale RP, Gertz MA, Gibson J, Giralt SA, Keating A, Kyle RA, Maharaj D, Marcellus D, McCarthy PL, Milone GA, Nimer SD, Pavlovsky S, To LB, Weisdorf DJ, Wiernik PH, Wingard JR, Vesole DH. Reece DE, et al. Bone Marrow Transplant. 2003 Dec;32(12):1135-43. doi: 10.1038/sj.bmt.1704288. Bone Marrow Transplant. 2003. PMID: 14647267 Review.

7

The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.

Chang H, Sloan S, Li D, Zhuang L, Yi QL, Chen CI, Reece D, Chun K, Keith Stewart A. Chang H, et al. Br J Haematol. 2004 Apr;125(1):64-8. doi: 10.1111/j.1365-2141.2004.04867.x. Br J Haematol. 2004. PMID: 15015970 Free article.

8

p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.

Chang H, Qi C, Yi QL, Reece D, Stewart AK. Chang H, et al. Blood. 2005 Jan 1;105(1):358-60. doi: 10.1182/blood-2004-04-1363. Epub 2004 Aug 31. Blood. 2005. PMID: 15339849 Free article.

9

IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.

Wechalekar A, Amato D, Chen C, Keith Stewart A, Reece D. Wechalekar A, et al. Ann Hematol. 2005 Feb;84(2):115-7. doi: 10.1007/s00277-004-0944-x. Epub 2004 Oct 22. Ann Hematol. 2005. PMID: 15503021

10

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK. Trudel S, et al. Blood. 2005 Apr 1;105(7):2941-8. doi: 10.1182/blood-2004-10-3913. Epub 2004 Dec 14. Blood. 2005. PMID: 15598814 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

271 results

Search Page

Filters